A Metabolomic Approach to Probing Myocardial Fuel Shifts in Human Heart Failure
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/19/2016 |
| Start Date: | March 2017 |
| End Date: | February 2018 |
| Contact: | Eileen Handberg, PhD |
| Email: | eileen.handberg@medicine.ufl.edu |
| Phone: | 352-273-9082 |
This proposal is designed to test the hypothesis that humans shift to reliance on ketone
bodies as a cardiac fuel source during the development of HF. The investigator also propose
that this shift to ketone utilization can be detected by metabolomic profiling of blood.
Specific Aim 1: To determine if the failing human heart exhibits increased extraction of
blood-borne ketone bodies. Ketone bodies will be measured in coronary sinus, arterial, and
central venous blood samples to determine AV differences. The HF group will be comprised of
patients undergoing cardiac resynchronization therapy with an implantable
cardioverter-defibrillator. The Control group will be compromised of patients without
evidence of structural heart disease who are undergoing catheter ablation for
supraventricular tachycardia.
Specific Aim 2: To determine whether blood samples from humans with HF display metabolomic
signatures indicative of increased myocardial ketone body utilization. Quantitative targeted
metabolomics will be performed on the samples described in Aim 1 to determine if metabolite
markers (e.g. C4-OH acylcarnitine, acetylcarnitine, succinate) found to be associated with
increased myocardial ketone body oxidation in animal models are increased in the human HF
group compared to the controls.
bodies as a cardiac fuel source during the development of HF. The investigator also propose
that this shift to ketone utilization can be detected by metabolomic profiling of blood.
Specific Aim 1: To determine if the failing human heart exhibits increased extraction of
blood-borne ketone bodies. Ketone bodies will be measured in coronary sinus, arterial, and
central venous blood samples to determine AV differences. The HF group will be comprised of
patients undergoing cardiac resynchronization therapy with an implantable
cardioverter-defibrillator. The Control group will be compromised of patients without
evidence of structural heart disease who are undergoing catheter ablation for
supraventricular tachycardia.
Specific Aim 2: To determine whether blood samples from humans with HF display metabolomic
signatures indicative of increased myocardial ketone body utilization. Quantitative targeted
metabolomics will be performed on the samples described in Aim 1 to determine if metabolite
markers (e.g. C4-OH acylcarnitine, acetylcarnitine, succinate) found to be associated with
increased myocardial ketone body oxidation in animal models are increased in the human HF
group compared to the controls.
After subjects agree to participate in this study and are scheduled to have cardiac
resynchronization therapy, the research personnel will take 1 teaspoon of blood before and
after the scheduled cardiac procedure for comparison.
Once subjects agree to participate in this study and are scheduled to have a catheter
ablation procedure, research personnel will take 1 teaspoon of blood during the scheduled
cardiac procedure.
These samples will be taken from catheters already placed during the scheduled cardiac
procedure.
Blood will be sent to a lab at the Sanford-Burnham Metabolomics Core Facility in Orlando,
Florida for analysis.
resynchronization therapy, the research personnel will take 1 teaspoon of blood before and
after the scheduled cardiac procedure for comparison.
Once subjects agree to participate in this study and are scheduled to have a catheter
ablation procedure, research personnel will take 1 teaspoon of blood during the scheduled
cardiac procedure.
These samples will be taken from catheters already placed during the scheduled cardiac
procedure.
Blood will be sent to a lab at the Sanford-Burnham Metabolomics Core Facility in Orlando,
Florida for analysis.
Inclusion Criteria:
- Undergoing cardiac resynchronization therapy
- Undergoing sinus cannulation
Exclusion Criteria:
- NYHA class II-IV heart failure
We found this trial at
1
site
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
